Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (536) 536
humans (423) 423
animals (264) 264
cholesterol (181) 181
male (180) 180
female (156) 156
mice (151) 151
proteins (149) 149
proprotein convertase 9 (148) 148
proprotein convertases (143) 143
multidisciplinary sciences (133) 133
pcsk9 (110) 110
hypercholesterolemia (102) 102
lipids (98) 98
research (98) 98
cholesterol, ldl - blood (97) 97
low density lipoproteins (94) 94
middle aged (93) 93
lipoproteins (92) 92
proprotein convertases - metabolism (89) 89
subtilisin (87) 87
serine endopeptidases - genetics (85) 85
biochemistry (84) 84
expression (84) 84
research article (84) 84
serine endopeptidases - metabolism (82) 82
kexin (81) 81
medicine (81) 81
enzymes (80) 80
biochemistry & molecular biology (79) 79
mutation (79) 79
statins (78) 78
analysis (76) 76
physiological aspects (75) 75
science (74) 74
furin (72) 72
proprotein convertases - genetics (72) 72
serine endopeptidases - immunology (72) 72
cell biology (71) 71
antibodies, monoclonal - therapeutic use (70) 70
proprotein convertases - immunology (70) 70
adult (69) 69
rodents (69) 69
abridged index medicus (68) 68
low density lipoprotein (68) 68
cardiovascular disease (66) 66
gene expression (65) 65
monoclonal antibodies (64) 64
atherosclerosis (61) 61
risk factors (61) 61
hypercholesterolemia - drug therapy (60) 60
immunology (60) 60
proprotein convertase 9 - antagonists & inhibitors (59) 59
cardiac & cardiovascular systems (56) 56
cells (56) 56
metabolism (56) 56
receptors, ldl - metabolism (56) 56
aged (55) 55
genetic aspects (55) 55
amino acid sequence (53) 53
endocrinology & metabolism (53) 53
monoclonal-antibody (53) 53
proprotein convertase 9 - immunology (53) 53
proprotein convertases - antagonists & inhibitors (53) 53
subtilisin/kexin type 9 (53) 53
cell line (52) 52
article (51) 51
biology (51) 51
anticholesteremic agents - therapeutic use (50) 50
density-lipoprotein cholesterol (50) 50
genetics (49) 49
proteases (49) 49
mice, inbred c57bl (48) 48
molecular sequence data (47) 47
proprotein convertase (47) 47
activation (46) 46
health aspects (46) 46
receptor (46) 46
familial hypercholesterolemia (45) 45
gene (45) 45
liver (45) 45
biological sciences (44) 44
diabetes (44) 44
proteolysis (44) 44
treatment outcome (44) 44
antibodies (42) 42
cardiovascular diseases (42) 42
proprotein convertase 9 - metabolism (42) 42
rats (42) 42
receptors, ldl - genetics (42) 42
peptides (41) 41
lipoprotein receptors (40) 40
medical research (40) 40
studies (40) 40
amino acids (39) 39
genes (39) 39
heterozygous familial hypercholesterolemia (39) 39
inflammation (39) 39
clinical trials (38) 38
ldl cholesterol (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (563) 563
Chinese (2) 2
Italian (2) 2
Spanish (2) 2
French (1) 1
German (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE3Leiden.CETP mice
by Landlinger, C and Pouwer, MG and Juno, C and van der Hoorn, JWA and Pieterman, EJ and Jukema, JW and Staffler, G and Princen, HMG and Galabova, G
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2499 - U143
Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and... 
CARDIAC & CARDIOVASCULAR SYSTEMS | APOE3Leiden.CETP mice | CARDIOVASCULAR EVENTS | Anti-PCSK9 vaccine | PCSK9 | MECHANISMS | STATINS | CHRONIC DISEASES | IMMUNIZATION | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | Atherosclerosis | Systemic and vascular inflammation | DEGRADATION | ASSOCIATION | Biomarkers - metabolism | Hypercholesterolemia - immunology | Antibodies - metabolism | Cholesterol, HDL - metabolism | NLR Family, Pyrin Domain-Containing 3 Protein - metabolism | Plaque, Atherosclerotic - prevention & control | Mice, Transgenic | Vaccines, Subunit - immunology | Vasculitis - prevention & control | Proprotein Convertase 9 - immunology | Vasculitis - immunology | Coronary Disease - prevention & control | Intercellular Adhesion Molecule-1 - metabolism | Animals | NLR Family, Pyrin Domain-Containing 3 Protein - immunology | Proprotein Convertase 9 - antagonists & inhibitors | Vaccines, Subunit - administration & dosage | Apolipoprotein E3 - deficiency | Aortic Diseases - prevention & control | Female | Hypercholesterolemia - prevention & control | Atherosclerosis - prevention & control | Disease Models, Animal | Index Medicus | Basic Science | Editor's Choice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
by Ridker, Paul M and Revkin, James and Amarenco, Pierre and Brunell, Robert and Curto, Madelyn and Civeira, Fernando and Flather, Marcus and Glynn, Robert J and Gregoire, Jean and Jukema, J. Wouter and Karpov, Yuri and Kastelein, John J.P and Koenig, Wolfgang and Lorenzatti, Alberto and Manga, Pravin and Masiukiewicz, Urszula and Miller, Michael and Mosterd, Arend and Murin, Jan and Nicolau, Jose C and Nissen, Steven and Ponikowski, Piotr and Santos, Raul D and Schwartz, Pamela F and Soran, Handrean and White, Harvey and Wright, R. Scott and Vrablik, Michal and Yunis, Carla and Shear, Charles L and Tardif, Jean-Claude and SPIRE Cardiovascular Outcome Inve and SPIRE Cardiovascular Outcome Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events... 
TRIALS | MEDICINE, GENERAL & INTERNAL | EVENTS | METAANALYSIS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: An analysis of 10 clinical trials and the LDL receptor's role
by Raal, Frederick J and Giugliano, Robert P and Sabatine, Marc S and Koren, Michael J and Blom, Dirk and Seidah, Nabil G and Honarpour, Narimon and Lira, Armando and Xue, Allen and Chiruvolu, Padmaja and Jackson, Simon and Di, Mei and Peach, Matthew and Somaratne, Ransi and Wasserman, Scott M and Scott, Rob and Stein, Evan A
Journal of Lipid Research, ISSN 0022-2275, 06/2016, Volume 57, Issue 6, pp. 1086 - 1096
Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9... 
Proprotein convertase subtilisin/kexin type 9 | Low density lipoprotein receptor | Lipoprotein (a) | Low density lipoprotein cholesterol | NONHUMAN-PRIMATES | kexin type 9 | proprotein convertase subtilisin | EFFICACY | BIOCHEMISTRY & MOLECULAR BIOLOGY | SUBTILISIN/KEXIN TYPE 9 | RANDOMIZED-TRIAL | low density lipoprotein receptor | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | lipoprotein (a) | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | low density lipoprotein cholesterol | CARDIOVASCULAR RISK | AMG 145 | Proprotein Convertase 9 - antagonists & inhibitors | Humans | Receptors, LDL - biosynthesis | Cholesterol, LDL - metabolism | Receptors, LDL - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Clinical Trials as Topic | Proprotein Convertase 9 - metabolism | Proprotein Convertase 9 - immunology | Lipoprotein(a) - metabolism | Hep G2 Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
by Ridker, Paul M and Tardif, Jean-Claude and Amarenco, Pierre and Duggan, William and Glynn, Robert J and Jukema, J. Wouter and Kastelein, John J.P and Kim, Albert M and Koenig, Wolfgang and Nissen, Steven and Revkin, James and Rose, Lynda M and Santos, Raul D and Schwartz, Pamela F and Shear, Charles L and Yunis, Carla and SPIRE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1517 - 1526
In six trials comparing the anti–PCSK9 antibody bococizumab with placebo, the reduction in LDL cholesterol at 12 weeks was 55.2 percentage points lower with... 
TRIALS | MEDICINE, GENERAL & INTERNAL | EFFICACY | CARDIOVASCULAR EVENTS | STATIN THERAPY | SAFETY | REDUCING LIPIDS | VASCULAR EVENTS | RISK | MONOCLONAL-ANTIBODY | Hypercholesterolemia - immunology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Proprotein Convertase 9 - blood | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Complications and side effects | Treatment outcome | Immune response | Patient outcomes | Analysis | Dosage and administration | Antilipemic agents | Lipoproteins (low density) | Hyperlipidemia | Clinical trials | Lipids | Subtilisin | Apolipoproteins | Patients | Low density lipoprotein | Cholesterol | Studies | Apolipoprotein B | Kexin | Monoclonal antibodies | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis
by Cao, Ye‐Xuan and Liu, Hui‐Hui and Dong, Qiu‐Ting and Li, Sha and Li, Jian‐Jun
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1391 - 1398
Aims: To investigate the effect of two clinically applied proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9-mAbs) on glycaemia and... 
PCSk9‐mAb | meta‐analysis | glucose metabolism | new‐onset diabetes mellitus | meta-analysis | PCSk9-mAb | new-onset diabetes mellitus | ADD-ON | LDL-C | GENETIC-VARIANTS | INHIBITOR ALIROCUMAB | DENSITY-LIPOPROTEIN CHOLESTEROL | REDUCING LIPIDS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | SERINE-PROTEASE | AMG 145 | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hypercholesterolemia - blood | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Anticholesteremic Agents - therapeutic use | Fasting - blood | Cholesterol, LDL - metabolism | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucose metabolism | Analysis | Physiological aspects | Monoclonal antibodies | Diabetes | Glucose | Dextrose | Lipoproteins (low density) | Diabetes mellitus | Homeostasis | Subtilisin | Low density lipoprotein | Cholesterol | Body mass index | Kexin | Hemoglobin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies, DS-9001A, albumin binding domain–fused anticalin protein
by Masuda, Yusuke and Yamaguchi, Shinji and Suzuki, Chikako and Aburatani, Takahide and Nagano, Yuki and Miyauchi, Ryuki and Suzuki, Eiko and Yamamura, Naotoshi and Nagatomo, Kentaro and Ishihara, Hidetoshi and Okuno, Kazuaki and Nara, Futoshi and Matschiner, Gabriele and Hashimoto, Ryuji and Takahashi, Tohru and Nishizawa, Tomohiro
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 05/2018, Volume 365, Issue 2, pp. 368 - 378
Since it was recently reported that an antibody for proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces the risk of cardiovascular events in a... 
NONHUMAN-PRIMATES | INHIBITION | CHOLESTEROL | ANACETRAPIB | GENE | LDL | DISEASE | LOW-DENSITY-LIPOPROTEIN | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | STATINS | Recombinant Fusion Proteins - immunology | Albumins - metabolism | Humans | Macaca fascicularis | Rats | Receptors, LDL - metabolism | Male | Atorvastatin - pharmacology | Proprotein Convertase 9 - immunology | Rats, Sprague-Dawley | Recombinant Fusion Proteins - metabolism | Hep G2 Cells | Animals | Drug Interactions | Lipocalins - genetics | Oxazolidinones - pharmacology | Protein Domains | Recombinant Fusion Proteins - genetics | Mice | Cholesterol Ester Transfer Proteins | Lipocalins - chemistry | Lipoproteins, LDL - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Discordant response of low density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
by Edmiston, Jonathan B and Brooks, Nathan and Tavori, Hagai and Minnier, Jessica and Duell, Bart and Purnell, Jonathan Q and Kaufman, Tina and Wojcik, Cezary and Voros, Szilard and Fazio, Sergio and Shapiro, Michael D
Journal of Clinical Lipidology, ISSN 1933-2874, 2017, Volume 11, Issue 3, pp. 667 - 673
Abstract Background Clinical trials testing proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated an unanticipated but... 
Cardiovascular | Low-density lipoprotein | Proprotein convertase subtilisin/kexin type 9 | Lipoprotein(a) | Cholesterol | Discordance | FAMILIAL HYPERCHOLESTEROLEMIA | RISK | RECEPTOR | LDL CHOLESTEROL | TRIAL | REDUCTION | PCSK9 INHIBITION | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | EVOLOCUMAB | AMG 145 | Humans | Middle Aged | Cholesterol, LDL - blood | Female | Male | Lipoprotein(a) - blood | Proprotein Convertase 9 - immunology | Antibodies, Monoclonal - immunology | Cohort Studies | Monoclonal antibodies | Cholesterol, LDL | Research | Lipoprotein A | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients
by Shen, Tong and James, Douglas E and Krueger, Kathryn A
Pharmaceutical Research, ISSN 0724-8741, 1/2017, Volume 34, Issue 1, pp. 185 - 192
LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density lipoprotein... 
Biochemistry, general | Biomedical Engineering | Biomedicine | LDL-C | Pharmacy | Medical Law | PCSK9 | Pharmacology/Toxicology | LY3015014 | MONOTHERAPY | CLINICAL-TRIAL | EFFICACY | EVOLOCUMAB AMG 145 | RANDOMIZED-TRIAL | EZETIMIBE | CHEMISTRY, MULTIDISCIPLINARY | DENSITY-LIPOPROTEIN CHOLESTEROL | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - pharmacokinetics | Male | Ezetimibe - administration & dosage | Healthy Volunteers | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Young Adult | Anticholesteremic Agents - pharmacokinetics | Antibodies, Monoclonal - administration & dosage | Immunoglobulin G - immunology | Anticholesteremic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Antibodies, Monoclonal - immunology | Hypercholesterolemia | Low density lipoproteins | Analysis | Immunoglobulin G | Body weight | Monoclonal antibodies | Statins | Proteins | Immunoglobulins | Pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9.